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Abstract 
At present, the prevalence of diseases concerning with the posterior segment is growing 
rapidly. These diseases include age-related macular degeneration (AMD), diabetic 
retinopathy, and proliferative vitreoretinopathy. Currently, drug delivery to the back of 
the eyes is performed mainly through intravitreal injection in clinical practice, while 
frequent injection requirement may cause some potential threat and concomitant 
diseases to the patients. Traditional eye drop administration is taken as the most 
acceptable way for patients to use. However, it has been believed that eye drop 
administration can hardly deliver the drug to posterior segment of the eyes owning to 
the barriers in ocular structures. Recently, it was reported that colloidal drug carrier 
system liposomal particles in eye drops may deliver drugs to the posterior segment of 
the eye. In this study, lipid emulsions and polymeric micelles were prepared and 
evaluated as candidates of colloidal drug delivery system for posterior segment diseases 
of the eye. The properties of drug carriers were investigated to enhance the delivery 
efficiency via topical administration and also to understand the transit mechanism.  
 
Particle design of lipid emulsion for ocular posterior segment delivery 
In order to analyze the delivery efficiency of colloidal carriers visually, fluorescence 
labeled lipid emulsion was prepared by formulating coumarin 6 (C-6). The formulation 
and preparing process were optimized to obtain fine particle size of dispersed droplets 
of 100 nm. In vivo study with mice, apparently fluorescence was observed on the retinal 
part of the eye after ophthalmic application of the lipid emulsion. It indicated that the 
lipid emulsion can work well as well as liposomal systems as a drug carrier for 
delivering the drug to the posterior segment of eye. The drug delivery efficiency of lipid 
emulsion was clarified to be relevant with the surface properties of carrier than the 
formulation properties.  Moreover, internalization of lipid emulsion particles 
containing C-6 with the eye tissue was assumed as an essential phenomenon in 
delivering C-6 to the posterior part of eye, because stability of lipid emulsions were 
confirmed by leakage of little amount of C-6. 
 
Polymeric micelles for enhancing drug delivery to posterior segment 
To evaluate the feasibility of polymeric micelles for drug posterior segment delivery, 
several formulations of Vitamin E TPGS (TPGS) and DSPE-PEG2000 (DSPE-PEG) 
were examined. Among these formulations, the molar ratio of 3:6 and 0:9 
(TPGS:DSPE-PEG) made the micelles fine particle size and spherical morphology. The 
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two types of micelles (3:6 and 0:9) showed almost the same level in delivery efficiency 
in vivo study, while cellular uptake was improved in vitro test when TPGS was 
incorporated in the micelle formulation. Combined with the endocytosis inhibition study, 
the drug delivery efficiency to posterior segment was concluded to be controlled by 
both internalization of colloidal carriers into ocular cells and the transportation of 
carriers in the ocular tissues.  
 
In conclusion, lipid emulsions and polymeric micelles might be good candidates of 
colloidal drug delivery systems to ocular posterior segment as well as liposomal 
systems. In addition, the surface properties and bio-stability of colloidal carriers were 
found to be important in improving the drug delivery to posterior segment in treatment 
of ophthalmic diseases. These conclusions might contribute greatly to development of 
ocular colloidal drug delivery systems targeting to posterior segment of the eye. 
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博士論文要旨 
高齢化社会が進む近年、糖尿病網膜症、加齢黄斑変性など後眼部の疾患の患者
数は増えている。これらの疾患の治療には、後眼部に薬物を送達する必要があ
るが、医療現場では、主として硝子体への注射が行われている。眼に注射する
ことは患者さんにとっては恐怖感があるばかりか、繰返しの注射は炎症などの
副作用も心配される。眼科領域の最も一般的な製剤である点眼剤では、薬物は
後眼部まで送達できないと考えられてきたが、近年、リポソームを用いて点眼
によって後眼部に送達ができることが報告された。本研究では、リポソームと
は異なる微粒子薬物キャリアであるリピッドエマルション、高分子ミセルがリ
ポソーム同様な後眼部送達機能を有するか評価した。これらの粒子の特性を検
討して、点眼後の後眼部送達効率を向上させる物理化学的性質などの影響につ
いて研究を行った。 
 
リピッドエマルションの粒子設計と後眼部送達機能の評価 
後眼部送達機能を視覚的に評価することを目的として、蛍光物質で標識したリ
ピッドエマルションを調製した。その際、100nm 程度の分散滴の粒子径となる
ように、処方および調製方法に関して最適化をした。得られた粒子を用いて、
マウスに点眼して後眼部送達機能を評価したところ、リポソーム同様な効果が
確認された。また、後眼部送達機能の観点では、処方よりも粒子の表面特性の
制御が重要であることが判った。さらに、後眼部送達は内封された物質がリリ
ースされて送達されるのではなく、封入されたまま、粒子の眼組織との親和性
により達成されると推定された。 
 
高分子ミセルによる後眼部送達 
高分子ミセルによる後眼部送達の可能性を検討するため、TPGS (Vitamin E 
TPGS) および DSPE-PEG (DSPE-PEG2000) の構成成分からなるミセル粒子の
調製を試みた。DSPE-PEGだけでも、微小なミセル粒子が形成されることが明ら
かとなった。さらに、このミセル粒子に適度な割合の TPGS を組み込むことが
可能であった。DSPE-PEG のみの処方および TPGS が細胞毒性を示さない 3:6 
( TPGS:DSPE-PEG ) の処方比においては、目的とする微小な粒子径を有す球形
度の高い粒子が得られることが明らかとなった。また、TPGS の処方によって細
胞親和性は高くなることが示されたが、実際の後眼部送達機能には大きな影響
を及ぼさなかった。細胞取り込みの阻害物質を用いた実験結果も考慮すると、
後眼部送達機能には、組織内の移行性も関与し、細胞取り込み実験の結果だけ
では判断できないという結論に至った。 
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以上の結果から、リピッドエマルション、高分子ミセルは、リポソームと同様
に、薬物を後眼部に送達するキャリアであることが明らかとなった。また、後
眼部への送達機能は、単に粒子のサイズだけではなく、粒子の表面特性、ある
いは、生体内での安定性などの要因があることが示された。本研究の結果は、
後眼部送達用点眼剤の開発に新たな知見を提供するものと考える。 
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Chapter 1:  
General introduction 
For the last decade, visual impairment from infectious diseases has decreased in virtue 
of overall socioeconomic development. However, in most countries, ocular posterior 
segment diseases have emerged as potential threats to the status of sight of the people. 
At present, it is assumed that more than 50% of the most enfeebling ocular diseases 
originated from the posterior part of the eyes [1]. Diabetic retinopathy has been added to 
the first by the increasing of diabetes among many population groups, while glaucoma, 
an eye disease known for centuries, remains on the public health agenda due to 
difficulties in its early diagnosis and frequent necessity of life-long treatment. 
Age-related macular degeneration (AMD) ranks next among the global causes of visual 
impairment with a blindness prevalence of 8~7%, which is the primary cause of visual 
deficiency in industrialized countries [2]. In addition, the world population is rapidly 
ageing. As reported, between 2000 and 2050, the proportion of the world's population 
over 60 years will double from about 11% to 22% [3]. With the aging population 
increasing, it could be expected that the more and more people will realize the threat of 
ocular posterior diseases by aging, which might cause irreversible vision loss if they 
were without any effective treatment.  
 
Drug delivery to the posterior segment of the eye, namely, retina, choroid, vitreous 
humor and optic nerve, is very important for treating these disorders. It has been shown 
that vascular endothelial growth factor (VEGF) is responsible for many ocular 
pathologies involving retina neovascularization. To inhibit this target, lots of new drugs 
were listed as candidates; some of them have been already commercially available for 
intraocular use, such as Pegaptanib (Macugen®), Ranibizumab (Lucentis®), 
Bevacizumab (Avastin®) [4]. Moreover, increasing new agents for various therapeutic 
targets found would become potential liberators for patients who suffer from ocular 
posterior segment disease. Consequently, the problems facing to therapy of ocular 
posterior delivery can be assumed not to be lack of therapeutic agents. Developments of 
effective delivery methods of these agents to the objective site are strongly required. 
 
Currently, the intravitreal route is widely used to deliver therapeutic entities to the retina 
in clinical practice. However, frequent administration requirements via this route would 
lead to retinal detachment, endophthalmitis, retinal hemorrhage, increased intraocular 
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pressure, and eye pain [5]. To minimize some of these complications, various controlled 
delivery systems have been developed in the form of biodegradable or 
non-biodegradable implants. Even so, there are still several other aspects of this 
treatment need to be addressed, including the long term stability of the implants and the 
possibility of retinal neuron response caused by long time stimulation [6]. In addition, 
drug delivery through periocular route seems to enable the diffusion of drug molecules 
directly to the external surface of the sclera bypass the elimination of drugs through the 
conjunctival lymphatics or even episcleral veins. Therefore, the periocular route is 
considered to be the least painful and efficient route of drug delivery to the posterior eye, 
because the route could minimize the risk of retina damage associated with intravitreal 
route of administration [7]. However, owing to the tight conjunctions of retinal pigment 
epithelium (RPE) and a network of blood vessels located between the sclera and retina, 
only few compounds with adequate permeability and the concentration gradient could 
flux across these barriers and reach to the retina [8,9].  
 
Besides, the systemic route is also severely limited in effectively delivering drugs to the 
back of the eye. As reported, only estimated 1-2% of compounds could delivery via this 
route successfully cross the blood aqueous barrier (BAB) and blood retinal barrier 
(BRB) to reach and accumulate in the retinal tissues [10]. Thus, the higher dose of drug 
for administration may be required to reach the therapeutic concentration within the 
retinal tissues. However, it will increase the potential side effects of systemically 
exposure the body under high concentration of drugs, which makes systemic 
administration an undesirable route of delivery for posterior segment therapies. In 
general, these methods are invasive ones, which associated with requirements of 
medical facilities, low compliances and higher adverse effects.  
 
Therefore it is important to develop a simple and less invasive way for delivering the 
drugs effectively to targeted tissues in the posterior segment of the eye. A topical eye 
drop represents the least invasive method for ocular delivery. However, the existence of 
anatomical and physiological barriers make eye drop administration difficult to 
accomplish effective drugs to targeted anterior tissues not to mention the posterior 
segment, such as cornea/conjunctiva barriers, the challenge of drug distribution, 
metabolism and clearance [13]. 
 
Recent developments in colloidal carriers for ocular drug delivery provided new 
potentials for posterior segment delivery via topical ophthalmic administration. In 2009, 
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Hironaka and co-workers first described drug delivery to the posterior segment of the 
eye using submicron-sized (100 nm) liposomes as the carriers [11]. In addition, 
nano-structured lipid carriers, were highlighted for their ability to deliver drugs to the 
retina after topical application [19]. The particle size, composition, and surface 
properties of colloidal carriers were reported to be important for the posterior segment 
delivery of drugs in previous researches [12,16,17]. It is also conceivable that 
endocytosis seem to be the main uptake mechanism for the drug loaded carriers on the 
surface of the eyes in delivering drugs to the posterior segment. Considering to these 
drug delivery beneficial properties, typical colloidal carrier lipid emulsions and 
polymeric micelles composited with biocompatibility materials seem to be potential 
candidates for ocular drug delivery as well as liposomal systems. 
 
The purpose of this study was to apply the lipid emulsions and Vitamin E 
TPGS/DSPE-PEG2000 micelles for ocular delivery and to illuminate their feasibility 
for topical drug posterior segment delivery. In addition, to understand the transit 
mechanism, a variety details were collected and analyzed to reveal the possible transit 
routes of colloidal drug delivery systems to posterior segment of the eye. 
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Chapter 2: 
Lipid emulsion for ocular posterior segment delivery 
2.1 Introduction 
Over the past several decades, emulsions, as one of typical dosage forms, have been 
explored for resolving a variety of drug delivery challenges. An emulsion system can be 
normally taken as a mixture of two immiscible phases (normally, water and oil) with 
emulsifier to stabilize one dispersed in the other (Fig.2-1).  
 
 
 
 
 
 
 
 
 
      
Fig.2-1 Scheme of emulsion 
 
As concern the side effect of surfactants, the most common used emulsifier in emulsion 
formulations is lecithin (phosphatidylcholine) normally derived from egg yolk or 
soybean. The emulsion, in which oily materials are dispersed in an aqueous phase with 
lecithin was called lipid emulsions (LEs). LEs dispersed as submicron-sized droplets 
has been accepted for their good biocompatibility and well known as a parenteral 
nutrition. The parenteral nutritional LEs have been applied to patients for supplying 
high-caloric nutrition in many countries. As LEs can incorporate lipophilic drugs, it has 
been applied to design parenteral drug delivery systems also in aims of reducing side 
effects, increasing the bioavailability, and prolonging the pharmacological effects [16]. 
A variety of poorly water soluble drugs loaded emulsion formulations for intravenous 
injection have been marketed in a lot of countries for solubilizing and improving 
delivery also [17,18]. 
 
In the field of ocular dose forms, lipid emulsion systems have also been used to provide 
a better balance between ocular bioavailability improvement and patient comfort via 
Oil 
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instillation [19]. Some of them have already been commercialized in the markets. An 
anionic LEs containing 0.05% cyclosporine A (Restasis
®
, Allergan, Irvine, USA), was 
first approved by FDA for anterior segment disease (chronic dry eye). Subsequently, a 
number of cationic emulsion formulations, such as Cationorm
®
 and Novasorb
®
, were 
proved to be efficient drug delivery for dry eye syndrome and cure anterior segment 
diseases. As could be noticed previously, there has been few researches focused on 
targeting to the ocular posterior segment. 
 
In the present study, we hypothesized that submicron-sized LEs would be suitable for 
drug delivery to the posterior segment via eye drops administration. As previously 
reported, liposome could behave as a drug carrier for delivering drugs to posterior 
segment of the eye in virtue of endocytosis [11]. In view of the same surface structure of 
LEs with liposome covered with the phospholipid, LEs was assumed to be a potential 
candidate for drug posterior segment delivery.  
 
In order to testify the hypothesis, submicron-sized (100 nm) LEs were prepared and 
examined their feasibility in applying to topical ocular posterior segment delivery test. 
Subsequently, the formulation effects on retinal drug delivery efficiency were tested by 
different emulsion formulations with different types of core oils and emulsifiers. Finally, 
to improve the drug delivery efficiency, the surface of submicron-sized LEs was 
modified with functional polymers, chitosan (CS) and poloxamer 407 (F127). 
 
2.2 Preparation and characterization of lipid emulsion 
The formation of LEs relies on the emulsifiers to stabilize the emulsion by reducing 
interfacial tension between the oil and the water phases. In the current study, 
submicron-sized LEs were prepared using typical high-pressure homogenizer method 
and by means of emulsion phase inversion (Method A in Fig. 2-2) [20]. 
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Fig.2-2 Scheme of the emulsification procedure (W: water phase; O: oil phase). Method 
A: first water-in-oil droplets are produced; those inverted structures merge together to 
give elongated and bicontinuous or lamellar structures that finally decompose into 
submicron-sized oil droplets. Method B: small oil droplets are immediately produced 
and grow in size upon oil and surfactant addition. Their size is a result of the 
mechanical process only. (Reference to [20]) 
 
By the slow addition of water phase into the oil phase, with increasing the ratio of the 
water phase, the formulation experienced a phase transition from water in oil emulsion 
to oil in water emulsion, which was believed to have ability to formulate homogeneous 
small-sized droplets and stabilize the formulation [20]. Preliminary investigations 
revealed that the particle size of oily droplets in formulations decreased dramatically by 
using high pressure homogenizer under the conditions at 150MPa for 5 min. Under 
these conditions, stable and uniform lipid emulsions in the size around 100 nm with low 
polydispersity at the final pH about 7.4 were obtained after pH adjustment. The optimal 
weight ratio between emulsifier and oil phase was also found to be 3:10 for the 
formulation and high entrapment efficiency (~100%) was confirmed. Owing to the 
needle like crystallization of coumarin-6 (C-6), the portion of un-entrapped C-6 in the 
LEs was removed by filtration through 0.8μm membrane filter. The amount of C-6 
encapsulated in the oily droplet was determined by measuring C-6 concentration with 
and without filtration. C-6 assay was performed by using a fluorescent 
spectrophotometer; resultant calibration curve shown in Fig. 2-3 was used. The 
compositions and characteristics of different formulations of emulsion are presented in 
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Table 2-1.  
 
As could be noticed in Table 2-1, further increasing in castor oil ratio resulted in the 
increase in particle sizes and broadening in particle distribution. Owing to the higher 
viscosity of castor oil, the particle size of dispersed oil droplet in LEs increased and the 
higher energy was required to achieve the same particle level than emulsion made by 
Medium-chain triglycerides (MCT) as oil phase. In contrast, the particle size of the 
emulsion containing MCT as the only oil (Formulation A) could achieve an ideal 
particle size of 100 nm with a relatively narrow particle distribution. Since the 
emulsifier is an important determinant to enhance the stability of oily droplets, two 
kinds of natural phospholipids, egg yolk phospholipid (EPC) and hydrogenated soybean 
phospholipids (HSPC), were tested in the formulation study. The results indicated that 
both of the phospholipids own the same emulsifying capacity by producing same level 
of particle size. 
 
Table 2-1 Physical characterization of different lipid emulsions 
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Fig.2-3 Calibration curve of coumarin-6 by Fluorescent Spectrometer 
 
2.3 The delivery efficiency in vivo of lipid emulsion 
It has been reported that liposomes could deliver drugs to the ocular posterior segment 
via topical administration [11]. Structurally, liposomes are vesicles in which an aqueous 
volume is entirely enclosed by a membranous lipid bilayer mainly composed of natural 
or synthetic phospholipids [21]. Similarly, LEs is also a dispersed system, where oily 
droplets are dispersed in a water phase with the help of emulsifiers. The oily droplet 
surface of the LEs is covered by the phospholipid emulsifier indicating that the surface 
structure of LEs is almost the same as that of liposomes. Therefore, submicron-sized 
lipid emulsion systems have been expected for drug delivery to the posterior segment 
via eye drop administration in vivo. 
 
To evaluate the delivery efficiency of carriers, the fluorescence intensity on inner 
plexiform layer (IPL) of retina was quantified by Image J. The results were shown in 
Fig.2-4. Ganglion cell layer (GCL) is a layer of the retina that consists of retinal 
ganglion cells (RGC) and displaced amacrine cells. The death of RGC is reported to be 
a common feature of many ocular disorders such as glaucoma, optic neuropathies, and 
retinovascular diseases and so on [22]. In this study, the IPL was the region of interest 
and chosen as the target site because it is located close to the inner GCL of the retina, 
which is assumed to be the most suitable part to evaluate the delivery efficiency to the 
posterior segment. Compared to untreated eye, it was observed that significantly strong 
fluorescent intensity in the posterior ocular segment after one drop administration. 
However, this was not observed when MCT containing the same amount of C-6 was 
applied under the same conditions (Fig. 2-4). This result strongly suggested that MCT 
itself does not have delivery functions for the dissolving C-6. The very fine droplets of 
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LEs carriers are responsible for delivering C-6 to the posterior part of eye after topical 
administration.  
 
 
 
Fig.2-4 The effects of coumarin-6 loaded lipid emulsions on drug delivery to ocular 
posterior segment in mice. Representative epifluorescence microscopic images of the 
retina 30 min after eye drop administration. (A) Untreated (control); (B) 
coumarin-6-loaded lipid emulsion (Formulation A); (C) coumarin-6 dissolved in MCT; 
(D) the accumulated fluorescence intensity in the IPL after eye drop administration in 
mice. Data are shown as mean ± SEM. (n = 3). *P < 0.05 versus control. The scale bar 
represents 100 μm. GCL, ganglion cell layer; IPL, inner plexiform layer. 
 
2.4 The formulations effect on ocular drug delivery 
To compare the effect of formulations on drug delivery efficiency to the back of the eye, 
the normalized fluorescent intensity of C-6 on the IPL of the retina was calculated from 
the fluorescence images. As reported, particle size was considered to be one of 
important factors for intraocular drug delivery using liposomal drug delivery systems; 
100 nm was the best size for drug delivery to the posterior segment when comparing the 
delivery efficiency for the different particle sizes of liposome from 100 to 800 nm [15]. 
Therefore, we attempted to prepare LEs with particle sizes of approximately 100 nm 
with different formulations to clarify the formulations effect on drug ocular posterior 
segment delivery. Moreover, other formulation effects of LEs such as the types of inner 
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oil, phospholipids, on the delivery efficiency were evaluated. 
 
2.4.1 The effect of inner oil types 
Two kinds of core oils in the formulations were administrated based on their different 
physical and viscosity properties. In virtue of its less viscous, MCT was reported to be 
100 times more soluble in water than long chain triglycerides and had been well used in 
a lot of LEs formulations [14]. Castor oil is one of the most viscous oils reported to be 
commonly used in preparation of ophthalmic LEs [23]. Due to its high viscosity, it was 
difficult to prepare LEs of 100 nm with castor oil as the single oil phase even when 
increasing the working pressure of homogenizer. Therefore, a mixture of MCT and 
castor oil with ratios of 0.5:0.5 and 1:0 were used in vivo on comparing inner oil 
formulations effects on drug delivery to the ocular posterior segment. Negligible 
differences were observed on intraocular delivery efficiency between the different oil 
formulations (formulation A and B in Table 2-1), which suggested that the oil 
composition has little influence on drug delivery to the ocular posterior segment 
(Fig.2-5).  
 
 
 
Fig.2-5 Effects of core oil formulations on the efficiency of drug delivery to the retina. 
Representative epifluorescence microscopic images of the retina 30 min after eye drop 
administration. (A) Untreated (control); (B) MCT:Castor oil = 0.5:0.5 (Formulation B); 
(C) MCT:Castor oil = 1:0 (Formulation A); (D) the accumulated fluorescence intensity 
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in the IPL after eye drop administration in mice. Data are shown as mean ± SEM (n = 4). 
*P < 0.05 versus control. The scale bar represents 100 μm. GCL, ganglion cell layer; 
IPL, inner plexiform layer. 
 
2.4.2 The effect of phospholipid types 
The emulsifier effects on drug delivery to ocular posterior segments were determined by 
two types of eye drop emulsions prepared with EPC and HSPC as emulsifiers, 
respectively. They were selected in this study because both of EPC and HSPC have 
been commonly used in the formulation of emulsion and have significantly different 
phase transition temperatures (EPC, −15 to −17°C, HSPC 50 to 56°C) and 
unsaturated/saturated properties, respectively. Since both of the formulations (A and F 
in Table 2-1) revealed no apparently difference in delivery efficiency of C-6 to the IPL 
of the retina in mouse (Fig. 2-6), it was concluded that the properties of phospholipids 
in the formulations do not influence drug delivery efficiency to the ocular posterior 
segment in the same manner as the core oil composition. 
 
  
 
Fig.2-6 The effect of emulsifiers in lipid emulsion on the efficiency of drug delivery to 
the retina. Representative epifluorescence microscopic images of the retina 30 min after 
eye drop administration. (A) Untreated (control); (B) EPC emulsion (Formulation A); 
(C) HSPC emulsion (Formulation F); (D) the accumulated fluorescence intensity in the 
IPL after eye drop administration in mice. Data are shown as mean ± SEM (n = 4). *P < 
0
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0.05 versus control. The scale bar represents 100 μm. GCL, ganglion cell layer; IPL, 
inner plexiform layer. 
 
2.5 Surface modification for enhancing the trans-ocular posterior delivery 
 
2.5.1 The effect of surface charge of lipid emulsion 
Surface properties of LEs are important factors for the interaction of emulsion droplets 
with ocular cells and tissues. Negatively charged and positively charged emulsions were 
prepared using dicetylphosphate (DCP) and stearylamine (SA) as charge inducers, 
respectively (Formulation A and G in Table 2-1). The positively charged emulsion 
showed significantly higher delivery efficiency to the retina than the negatively charged 
in the ocular drug delivery study (Fig.2-7). It was considered that the bio-adhesive 
properties of cationic emulsion contributed to ocular drug delivery on account of the 
cell membrane naturally negatively charged [24]. EI-Shabouri has reported the similar 
results using positively charged nanoparticles to improve drug oral bioavailability [25]. 
These evidences suggest that the electrostatic interactions between the positively charge 
of the emulsion and the negatively charged cell membranes on the ocular surface 
enhanced the association, thereby increasing the interaction of the droplet with eye 
tissues. It was confirmed that the surface property of LEs seems to have much more 
influences on delivery efficiency to ocular posterior segment than the inner structure or 
the inner properties of LEs. 
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Fig.2-7 The effect of surface charge in the lipid emulsion on the efficiency of drug 
delivery to the retina. Representative epifluorescence microscopic images of the retina 
30 min after eye drop administration. (A) Untreated (control); (B) DCP-modified 
emulsion (Formulation A); (C) SA-modified emulsion (Formulation G); (D) the 
accumulated fluorescence intensity in the IPL after eye drop administration in mice. 
Data are shown as mean ± SEM (n = 4). *P < 0.05 verses control. **P < 0.05 verses 
negative charge emulsion. The scale bar represents 100 μm. GCL, ganglion cell layer; 
IPL, inner plexiform layer. 
 
2.5.2 The effect of surface modification with polymers 
Several surface modification techniques for colloidal drug carriers have been developed 
by using several polymers for the purpose of improving drug delivery [26,27]. 
Biodegradable cationic polymers such as chitosan (CS) have often been used to improve 
the mucoadhesive properties and cell association of colloidal drug carriers [28,29]. In 
addition, it has been reported that surface modification by a nonionic surfactant could 
increase the cellular association of nanoparticles [30]. Thus, two kinds of surface 
modifiers, CS and Pluronic® F-127 (F127) were selected to modify the surface of LEs 
for enhancing the drugs delivery efficiency to the posterior part of eyes. 
 
The particle size and zeta potential of the CS-modified emulsion changed from 89.25 
nm to 94.49 nm and −34.6 mV to −14.9 mV, respectively. The slight changes in particle 
size were supposed to result from surface modification with CS. The increasing in zeta 
potential confirmed the electrostatic interactions by the adsorption of positively charged 
CS on the surface of negatively charged emulsion particles. CS is a well-known 
biodegradable polymer that has been demonstrated excellent ocular compatibility with 
positive charge [31]. DCP was firstly used to induce a negative charge on the LEs. 
Therefore, the amino groups attached to the chain of CS molecule could interact with 
the phosphate groups of DCP incorporated in the emulsion particles electrostatically. 
The fluorescence intensity of C-6 in the retina increased by CS-modified emulsions 
compared with unmodified ones (Fig. 2-8). It suggested that CS modification could 
apparently enhance the ocular delivery efficiency of LEs to the posterior segment. The 
function of CS to open the tight conjunction of cells may be partly responsible for 
increasing drug delivery [32]. In addition, the residual amino acid groups, which do not 
interact with the negative phosphate group of DCP on the emulsion surface, may 
electrostatically interact with negatively charged mucus of eye surface tissue to prolong 
the retention time of emulsions. 
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In the case of F127 modification, the particle size and zeta potential of LEs were 
changed from 89.25 nm to 110.6 nm and −34.6 mV to −42.7 mV, respectively. 
Polyoxyethylated nonionic surfactants have been reported to increase drug permeability 
through corneal epithelial cell membranes [33]. F127, as a type of nonionic surfactants, 
is a thermosensitive amphiphilic polymer. With increasing the temperature, it could 
form gel in a certain concentration [34]. Furthermore, it was reported 5% (w/v) of F127 
indicated excellent ocular tolerance in eye irritation test [35]. With consideration of the 
irritation and cytotoxicity, 5% (w/v) was used in the study, although the thermosensitive 
property could not appear under this concentration. As shown in Fig. 2-8, it was 
indicated that F127 modified LEs significantly enhanced the drug delivery efficiency to 
the retina. The reason for delivery improvement by F127 was taken to be different from 
that of CS. One possibility is that F127 in the emulsion systems may increase the 
fluidity of cell membrane on the eye surface, leading to increase C-6 permeability. The 
other possibility is that the presence of F127 helped stabilize the LEs by increasing the 
viscosity in the system, thereby prolonging its retention time on the surface of the eye 
[34]. Above all, our data suggested that the positive surface properties of LEs have large 
impacts than their inner formulation properties on drug delivery to ocular posterior 
segment. 
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Fig.2-8 The effect of CS and P407 surface modification on delivery efficiency in mice 
retina. Representative epifluorescence microscopic images of the retina 30 min after eye 
drop administration. (A) Untreated (control); (B) unmodified lipid emulsion; (C) 
CS-modified lipid emulsion; (D) F127-modified lipid emulsion; (E) The accumulated 
fluorescence intensity in the IPL after eye drop administration in mice. Data are shown 
as mean ± SEM (n = 3). *P < 0.05 versus control. **P < 0.05 versus unmodified. The 
scale bar represents 100 μm. GCL, ganglion cell layer; IPL, inner plexiform layer. 
 
2.6 In vitro release study 
In order to clarify delivery mechanism of C-6 entrapped in LEs on the surface of the eye, 
in vitro release behaviors were examined by dialysis method. Rarely drug release was 
observed even after 12 h (720 min) incubation in the release test. It further proofed that 
C-6 internalized into the ocular cells was not in a release manner on the surface of the 
eye. 
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Fig. 2-9 In vitro release study of coumarin-6 loaded lipid emulsion in simulated tears 
(pH 7.4).  
 
2.7 Transit routes illumination from surface to posterior segment of the eye 
Present understanding suggests there are three potential routes of drug penetration from 
the corneal/conjunctiva surface to the retina for local drug delivery (Fig. 2-10) [36]: 
(1)trans-vitreous, which  trans-corneal diffuse into aqueous humor then entry into 
vitreous subsequent distribution into the target posterior part; (2)periocular paths, 
permeation through the conjunctiva followed by diffusion across the sclera, choroid and 
retina; (3)uvea-sclera, drugs firstly trans-corneal pass into anterior chamber, and then 
reach to uvea-sclera tissues subsequent diffusion into posterior tissues. In order to 
elucidate the transit routes of the colloidal carriers to the posterior segment of the eye, 
the observation of the change of C-6 as a marker of LEs on entire of the eyes was 
carried out. 
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Fig. 2-10 Three potential routes for the penetration of topically applied ophthalmic 
drugs to the posterior segment. (1) The trans-vitreous route: trans-corneal diffusion 
followed by entry into vitreous and subsequent distribution to ocular tissues (blue line). 
(2) Periocular route: diffusion around the sclera followed by trans-scleral absorption 
(red line). (3) Uvea-scleral route: trans-corneal diffusion followed by progression 
through the uvea-sclera (green line). From Reference [36]  
 
The fluorescent micrographic picture was taken 30 min after topically administrating 
with LEs (Fig. 2-11). The photograph confirmed that LEs administration achieved a 
strong fluorescence level on the cornea, and relatively weaker level on the aqueous side 
on lens, while negligible fluorescence was observed on the vitreous side of lens. 
Observations of C-6 fluorescence on the cornea and aqueous side of lens indicated that 
the colloidal carriers containing C-6 access to ocular tissues by way of corneal 
penetration into aqueous humor of anterior chamber. However, the undetectable level on 
the vitreous side of lens represented that drugs were restricted to continue distribution. 
This drug distribution pattern may exclude trans-vitreous as mainly transit into the 
posterior segment of the eye for colloidal drug delivery systems by the existence of lens 
block the distribution of drugs to the retina as discussed in Fig. 2-10 route (1).  
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Fig. 2-11 A schematic representation of the entire eye 30 min after administration of 
lipid emulsion. (A) Cornea, (B) Lens aqueous side, (C) Lens vitreous side. 
 
To confirm the further drug distribution behavior on the posterior tissues such as retina, 
two images of ocular posterior parts and their fluorescent quantification were taken (Fig. 
2-12). As could notice, the fluorescent intensity of IPL of retina was shown to gradually 
decrease with regular directions. The diffusion of coumarin-6 moved from ocular cornea 
side (anterior side) across to optical nerve side (posterior side) in combine with 
distribution from sclera side to retina side. These data strongly suggested that the 
formulated colloidal carriers help drugs reach the posterior segment of the eye via the 
periocular trans-sclera route and combination of the uvea-scera route but not 
trans-vitreous route as shown in Fig. 2-10 routes (2) and (3).  
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Fig. 2-12 A schematic representation of the ocular posterior segment parts 30 min after 
administration of lipid emulsion. 
 
2.8 Conclusion 
The main objective in this chapter was to investigate the feasibility of LEs in ocular 
posterior delivery of drugs via topical administration. The formulation effects on the 
drug delivery process and potential transit routes were discussed also. The conclusions 
were listed as follow: 
 
(1) Very fine particle sized LEs (ca.100 nm) were achieved by using high pressure 
homogenizer. The formulations and operation conditions would affect the final 
physicochemical characteristics of LEs. 
 
(2) It was confirmed that LEs could enhance the hydrophobic drug posterior segment 
delivery in vivo. However, it would not achieve by the oil droplet loaded with the 
same level of C-6. Moreover, the lipid emulsion showed very slow released 
behavior in vitro. All these data suggested that the drug posterior segment delivery 
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was contributed by the colloidal structure but not in a released manner on the 
surface of the eye. 
 
(3) The positively charged and mucoadhesive functional polymer modified on the 
surface of LEs were important in improving the ocular drug posterior segment 
delivery. Nevertheless, the inner properties of the formulations showed little effect 
on the drug delivery. 
 
(4) The mechanisms underlying topical administration for drug posterior segment 
delivery was supposed that drug distribution was not trans-vitreous route uptake into 
the posterior tissues but via periocular tans-scleral route and accompanied by the 
uvea-sclera route.  
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Chapter 3:  
Polymeric micelles for enhancing trans-ocular 
absorption of hydrophobic drugs 
3.1 Introduction 
Nano sized spherical polymeric micelles, composed of an inner core and outer corona, 
are frequently considered to be promising drug delivery carriers. They are formed by 
amphiphilic block copolymers with the size between 10 nm to 100 nm at low critical 
micelle concentrations compared with those micelles made by low-molecular-weight 
ionic surfactants. Polymeric micelles have attracted increasing interests for their 
potential application to deliver various therapeutic compounds, such as hydrophobic 
drugs and gene-based therapy medicine. A number of studies have been reported in this 
field. Abdelbary and Tadros [37] discussed the application of block copolymer 
nano-micellar carriers as nose-to-brain targeted delivery system. Kataoka and 
co-workers described the progress of synthetic polymeric micelles for the intravenous 
delivery of chemotherapy drugs [38–40]. The polymeric micelles also have been well 
reported to be used as topical ocular delivery vehicle due to their good biocompatibility 
[41,42]. Although previous studies have demonstrated that polymeric micelles had a 
great potential to be employed as ocular drug delivery system, rarely researches focused 
on ocular posterior segment delivery. 
 
D-α-tocopheryl polyethylene glycol succinate (Vitamin E TPGS, or simply TPGS), an 
amphiphilic block copolymer, has been used to overcome multidrug resistance (MDR) 
and promote the drug delivery efficiency as an inhibitor of P-glycoprotein (P-gp). 
Owing to its relatively low critical micelle concentration (CMC) of 0.02% w/w, TPGS 
was considered to be an ideal biomaterial in developing various drug delivery systems 
[43,44], especially in combination with PEG-DSPE [45,46]. PEG-DSPE is a 
biocompatible, micelle-forming pegylated lipid, with different level of PEG modified. 
Micelles formed  by  N- (Carbonyl- methoxy polyethylene glycol 2000)- 
1,2-distearoyl-sn-glycero-3-phosphorethanolamine, sodium salt (DSPE-PEG) exhibit 
very low critical micelle concentration (CMC) of approximately 1 × 10
−6
 M. This is 
attributed to the strong hydrophobic driving force for self-assembly originating from 
two saturated 18-carbon acyl chains, which makes DSPE-PEG2000 an ideal material to 
construct micelles for drug delivery [47–49].  
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In applying the polymeric micelles composed of these PEG-modified block copolymers 
as drug delivery systems, the outer corona of the micelles is condensed layer of PEG 
which can act as an excellent repellent for biomolecules. Such pegylated micelles are 
assumed to be poorly immunogenic and antigenic [50]. Considering their low CMC, the 
formed micelles should be sufficiently stable to withstand dilution after instillation.  
 
In this study, we attempted to design and evaluate TPGS/DSPE-PEG polymeric micelles 
to reveal the potential for ocular posterior drug delivery and the effect of their 
formulations on delivery process via topical administration. 
 
3.2 Preparation and characterization of polymeric micelles 
In this study, micelles with TPGS and DSPE-PEG were processed using film casting 
method as described in the experimental section. The formation of polymeric micelles 
was prepared using various concentration and weight ratios of TPGS and DSPE-PEG. 
Four types of formulations were tested to characterized formation of the micelles of 
TPGS and DSPE-PEG. C-6 was added as a fluorescence marker in the formulations to 
detect their drug delivery in vivo. 
 
The obtained micelles containing C-6 were clear and transparent with the color of 
fluorescence green. As shown in Table 3-1, the mean particle size of the four 
formulations was approximately 10 nm and all formulations displayed a similar neutral 
zeta potential. The size and zeta-potential values were negligibly affected by the ratio of 
TPGS and DSPE-PEG. For orange needle like crystallization of C-6, the entrapment 
was carried out with filtration method. As shown in Table 3-1, almost 100% of C-6 was 
encapsulated into the polymeric micelles prepared with molar ratio of 9:0, 6:3, and 3:6 
(TPGS:DSPE-PEG). In the case of DSPE-PEG2000 micelles (0:9 of TPGS:DSPE-PEG), 
entrapment efficiency was decreased as low as ca. 50%. 
 
To confirm the formation of polymeric micelles, transmission electron microscopic 
(TEM) analyses with molar ratios of 3:6 and 0:9 are illustrated in Fig. 3-1. In both 
formulations, the resultant TEM photographs indicated formation of monodisperse 
spherical micelles particles, whose size was about 10 nm as measured by dynamic light 
scattering (DLS) (Table 3-1). In comparing the two formulations, the 3:6 micelles 
appeared to be somewhat irregular shape compared with that of 0:9 micelles (Fig. 3-1). 
Moreover, as seen in Fig. 3-1, the particles of 3:6 micelles showed better dispersibility 
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than that of 0:9 micelles, on account of 0:9 micelles regularly arranged in a nice pattern 
compared to 3:6 micelles. It was considered to be attributable to the interposition of 
TPGS (with shorter PEG segments and single hydrophobic chain) into the core of mixed 
micelles, which disturbed the regular arrangement of DSPE-PEG micelles and also 
changed the repulsive force among particles. From this viewpoint, the TEM study also 
confirmed the interposition of TPGS in each micelles but not TPGS and DSPE-PEG 
forming micelles separately.  
 
In addition, 0:9 polymeric micelles displayed aggregation in 24 h at ambient 
temperature. However, the other three formulations provided better stability of over one 
week in the refrigerator. These data suggested that the incorporation of TPGS in 3:6 
micelles formulation may help to disperse the micellar system and achieve better 
stability. 
 
Table 3-1 Summary of formulations, Particle Size, and Zeta potential of micelles 
 
The ratio of 
TPGS/DSPE-PEG2000 
TPGS 
(mM) 
DSPE-PEG 
(mM) 
Size
*
 
(nm) 
Zeta-potential
*
 
(mV) 
Entrapment 
Efficiency % 
9:0 6.6 0 18.1 -3.62 ~100 
6:3 4.4 2.2 10.1 1.05 ~100 
3:6 2.2 4.4 8.7 -1.35 ~100 
0:9 0 6.6 11.7 -3.01 46 
*Determined by DLS. 
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Fig. 3-1 Transmission electron microscopic image of coumarin-6-loaded 
TPGS/DSPE-PEG micelles with molar ratios of 3:6 (A) and 0:9 (B). 
 
3.3 Cytotoxicity study 
A human conjunctiva cell line was employed to investigate the cytotoxicity of blank and 
C-6 loaded polymeric micelles with four formulations shown in Table 3-1. TPGS has 
been well reported to use as a permeation enhancer, stabilizer, or emulsifier in drug 
delivery systems in several studies [43,51]. As shown in Fig. 3-2, the cellular viability 
decreased with increasing amount of TPGS in polymeric micelle formulations. However, 
DSPE-PEG single micelles showed great ocular tolerability. This indicated that the 
cytotoxicity of micelles exhibited a highly TPGS concentration dependent manner. In 
addition, encapsulated C-6 did not induce further cytotoxicity in contrast to that without 
C-6 encapsulated formulations. According to these data, the polymeric micelles 
prepared with molar ratio of 3:6 and 0:9 with good cellular viability were selected to use 
for further researches in the following sections. 
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Fig. 3-2 Cytotoxicity of TPGS/DSPE-PEG2000 mixed micelles with and without 
loaded C-6 in the conjunctiva cells. The concentration of the mixed micellar solution 
was 6.6 mM in all experiments irrespective of the molar ratios of the components. Data 
are presented as the mean ± SD (n = 4-8). N. S. means no significant difference was 
observed. 
 
3.4 In vitro release study 
In order to understand the release behavior of micelles, the in vitro release of C-6, from 
3:6 and 0:9 micelles were evaluated in an aqueous medium containing tween 80. As 
shown in Fig. 3-3, sustained drug release profiles were seen in both formulations, while 
3:6 micelles showed slightly faster release than 0:9 micelles. Moreover, very small 
amount of the drugs were released in the first 30 min from both formulations. 
Considering the short residence time (<5 min) of topically applied drugs and neglecting 
the influence of enzyme, it may suggest that during the retention time on the surface of 
the eye, only very little amount of drug was released after instillation. In addition, in the 
study 1% Tween 80 was added to the medium to create a sink condition, establishing a 
more ideal environment than present on the surface of the eye, which may suggest the 
micelles would be more stable after installation than observed in the vitro release study. 
All evidences indicated that both of 3:6 and 0:9 micelles are relatively stable resistant to 
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the incubation in vitro. 
 
 
Fig. 3-3 In vitro release profile of coumarin-6-loaded TPGS/DSPE-PEG2000 3:6 (♦) 
and 0:9 (■) micelles (mean ± SD, n = 3). 
 
3.5 Cellular uptake of polymeric micelles 
In order to elucidate the uptake behavior of the two polymeric micellar formulations, a 
preliminary internalization delivery study was conducted using confocal laser scanning 
microscope (CLSM) against conjunctiva cells. The results showed that TPGS 
incorporation was effective for model drug uptake into conjunctiva cells. In another 
word, 3:6 micelles indicated stronger cellular association than 0:9 micelles (Fig. 3-4). 
 
Moreover, both formulations showed great stability in the first 30 min incubation in the 
test. However, drug crystals were discerned after 1 h incubation of 3:6 micelles. This 
may resulted from the relatively high mobility of 3:6 micelles with faster drug release as 
well as the partial destruction of 3:6 micelles under ocular circumstance, while 0:9 was 
not. With increasing incubation time, crystallization increased and more amount of 
drugs were liberated from the micelles, as shown in Figs. 3-4(B-C). These results could 
prove that the interposition of single chain of TPGS into the core of 3:6 micelles, may 
cause a loosen structure, irregular shape and a better dispersion but with the loss of 
bio-resistant property. In the case of 0:9 micelles, aggregated fluorescent spots were 
observed instead of crystals after 2 h incubation. Based on these observations, it 
appeared that 0:9 micelles had better bio-stability on the surface of the ocular cells, and 
 33 
 
C-6 had a strong association with the hydrophobic chains of DSPE-PEG, which was not 
relived from the structures of micelles. This may explain the slower in vitro drug release 
rate and the lack of crystal precipitation for the 0:9 micelles. 
 
 
 
Fig. 3-4 Evaluation on the association of micelles with the conjunctiva cells via 
confocal laser scanning microscopy. D-α-tocopherol polyethylene glycol 1000 
succinate/DSPE-PEG2000 3:6 and 0:9 micelles were incubated for 30 min (A), (D), 1 h (B), 
(E) or 2 h (C), (F). 
 
3.6 Endocytosis inhibition study 
The main objective in this section was to study the uptake mechanism of polymeric 
micelles by endocytosis inhibition study for 3:6 polymeric micelles. As shown in Fig. 
3-5, the uptake of 3:6 polymeric micelles incorporating C-6 was significantly inhibited 
by both clathrin-dependent endocytosis inhibitor and caveolae-dependent endocytosis 
inhibitor. These results suggested that clathrin- and caveolae-dependent endocytosis 
were involved in conjunctiva cellular uptake of polymeric micelles. 
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Fig. 3-5 Uptake mechanism study of 3:6 polymeric micelles by conjunctiva cells. 
Confocal microscopy images of 3:6 polymeric micelles when conjunctiva cells were 
pretreated without (A) or with 10μg/mL chlorpromazine for 1 h to inhibit clathrin (B) 
and 1μg/mL filipin III for 1 h to inhibit caveolae endocytosis (C) and then treated with 
200 μL 3:6 micelles for 1 h. 
 
3.7 In vivo animal study 
The drug delivery efficiency of entrapped C-6 was assessed after topical eye drop of 3:6 
and 0:9 polymeric micelles. Measurement of fluorescent level on IPL was performed to 
estimate the drug posterior segment delivery efficiency. Data in Fig. 3-6 revealed the 
absence of any significance difference between 3:6 and 0:9 micelles, although both 
micelles exhibited promising drug delivery efficiency to the posterior segment of the 
eye compared to the untreated one. These results confirmed that both micellar systems 
were potential carriers to be used in ocular drug posterior delivery. However, it was 
slightly inconsistent with the data in CLSM uptake study. In view of topical 
administration, eye drop formulations experienced rapid elimination due to tear turnover, 
nasolacrimal drainage, non-productive adsorption, and other factors. The residence time 
of topically applied formulation is normally less than 5 min, and with tear dilution, only 
1%–5% of applied drugs can reach the intraocular tissues [41]. The drug delivery to the 
ocular posterior may result from two possibilities, the first one may be attributed to the 
released drugs on the surface of the eye, and the other one may be caused the 
internalization of drug carriers for delivering to the ocular posterior segment. Therefore 
it can be hypothesized that if the drug ocular delivery was mainly because of drugs 
released from carriers to the surface of the eye, the results of 3:6 micelles in vivo should 
appear to higher drug level delivery than 0:9 micelles. However, this was not the case 
here. As previously reported, the ocular posterior delivery of topically administrated 
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drugs was caused mainly by the endocytosis of hydrophobic drug carriers but not in a 
released manner [11,12]. This was in agreement with our results in the study, which 
indicated that ocular posterior segment delivery was not mainly caused by drugs 
released from carriers. In agreement with these researches, with considering the 
endocytosis inhibition results, we identified the endocytosis of micellar drug carriers as 
the main mechanism for drug ocular posterior delivery after topical administration [52]. 
Therefore, the retina delivery of the model drug was believed to be mainly affected by 
the penetration of intact micelles loaded with the drug on the surface of the eye.  
 
As discussed above, the interposition of TPGS contributed to the mobility of micelles 
and produced a positive effect on drug release in the case of 3:6 polymeric micelles. 
Furthermore, the incorporation of TPGS in 3:6 micelles significantly increased the 
ocular cell association and internalization compared with the case of 0:9 micelles. These 
results suggested that drug delivery to the posterior segment was not only related with 
the internalization of colloidal carriers in ocular cells on the surface of the eye after eye 
drop, but also well associated with the transitions of carriers in the ocular tissues, which 
may be relevant to the bio-stability of colloidal carriers during the delivery process. 
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Fig. 3-6 Epifluorescence microscopic images of the posterior segment 30 min after the 
topical administration of TPGS/DSPE-PEG2000 micelles with molar ratios of 3:6 (B), 
0:9 (C) and untreated (A). Changes in the measured median fluorescence intensity in the 
IPL after the administration of 3 μl of micelles were measured (D). Data are presented 
as the mean ± SEM. (n = 8–10). *P < 0.05 versus untreated. The scale bar represents 
100 μm. GCL, ganglion cell layer; IPL, inner plexiform layer. 
 
3.8 Conclusion 
The feasibility of TPGS/DSPE-PEG micelles for enhancing the trans-ocular posterior 
segment delivery of hydrophobic drugs was investigated in the chapter. Different molar 
ratio of formulations were prepared and evaluated. The conclusions were listed as 
follow: 
 
(1) The uniform and spherical micelles formulated by TPGS/DSPE-PEG with molar 
ratios of 3:6 and 0:9 showed good biocompatibility and were indicated to have good 
potential as drug carriers for topical ocular posterior segment delivery. 
 
(2) Although uptake study of the two formulations showed apparently difference in 
conjunctiva cells, the drug posterior delivery was indicated almost the same level. 
This result suggested that drug ocular posterior segment delivery was not only 
relative with the internalization of colloidal carriers on the surface of the eye but 
also well associated with the transitions of carriers in the ocular tissues, which could 
not determinate one-sided data. 
 
(3) The clathrin- and caveolae-dependent endocytosis was suggested to be involved in 
the conjunctiva cellular uptake of micelles in this study. 
 
(4) The involvement of permeation enhancer (TPGS) in the formulation may be 
beneficial to drug encapsulated, formulation stability and internalization on the 
surface of the eye, but with sacrificing the bio-stability of micellar carrier. This may 
help the internalization of colloidal drug carriers into surface of the eye, but in vivo 
data suggested the drug posterior segment delivery was also well associated with the 
integrity of the drug carriers during transition in the ocular tissue. 
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Experimental Methods 
Chapter 2 
2.1 Materials 
Egg phosphatidylcholine (EPC) and hydrogenated Soy L-α-phosphatidylcholine 
(HSPC) were purchased from Nippon Oil and Fats Co., Ltd. (Tokyo, Japan). 
Dicetylphosphate (DCP) and Stearylamine (SA) were supplied by Sigma Chemical Co. 
(St. Louis, MO, USA) and Tokyo chemical Industry Co., Ltd. (Tokyo, Japan), 
respectively. Medium chain triglyceride (MCT, Triester F-810) was supplied by Nikko 
Chemical (Tokyo, Japan). Castor oil was purchased from Wako Pure Chemical 
Industries Ltd (Osaka, Japan). Coumarin-6 was purchased from MP Biomedicals LLC 
(Illkirch, France). Oligo CS (Oligo Chitosan MW around 1000) was supplied by 
Katakura Chikkarin Co., Ltd. (Tokyo, Japan). P407 (Poloxamer 407) was supplied by 
BASF (Ludwigshafen, Germany). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) was purchased from Nakalai Tesque (Kyoto, Japan). 
 
2.2 Preparation of lipid emulsion 
Lipid emulsions were prepared using a high pressure homogenization system 
(Nanomizer, Yoshida Kikai Co., Ltd., Nagoya, Japan). In brief, purified phospholipids 
with DCP or SA and coumarin-6 were dissolved in MCT with gentle heating. Glycerol 
was dissolved in deionized water as the aqueous phase. To achieve a coarse emulsion, 
the two phases were heated separately to 70°C and then were emulsified using a 
high-shear mixer (Polytron homogenizer, Kinematica, Lucerne, Switzerland) at the 
speed of 12000 rpm for 5 min. This emulsion was then cooled to room temperature, the 
pH was adjusted to 8.0, and the desired volume was made up with purified water. 
Finally, the emulsion was homogenized into a fine mono-dispersed emulsion with the 
high pressure homogenizer under 150 MPa for 10 min.  
 
2.3 Surface modification of lipid emulsions with CS and P407 
The prepared lipid emulsions (Formulation A, Table 2-1) were then mixed with an 
appropriate amount of 0.4% w/v and 10% w/v solution of CS and P407 in HEPES 
buffer respectively to produce a final concentration of 0.2% and 5% w/v. The samples 
were then incubated 1 h at room temperature after gently stirring for 30 min.  
 
2.4 Determination of particle size and zeta potential 
The diameter of the dispersed oil droplets in the emulsions and the zeta potential were 
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analyzed using Zetasizer Nano-ZS (Malvern Instrument Ltd., Worcestershire, UK) at 
500 times dilution with deionized water at room temperature. 
 
2.5 Determination of entrapment efficiency 
In consideration of the crystallization properties of coumarin-6, the un-entrapped 
coumarin-6 will not dissolve in the water phase of emulsion. Therefore, the prepared 
lipid emulsion was passed through 0.8μm filter. Then the fluorescent intensity of 
coumarin-6 in the formulations was quantified by Fluorospectro Photometer. The 
entrapment efficiency of lipid emulsion loaded with coumarin-6 was calculated as 
followed formula:  
Entrapment efficiency % = Fluorescent intensity of lipid emulsion after 
filtration/Fluorescent intensity of lipid emulsion before filtration ×100 
 
2.6 Animal study 
2.6.1 Animal 
Male ddY mice (Japan SLC, Hamamatsu, Japan), 4 weeks old (30g-35g), were used as 
the animal model. All protocols were approved by the Institutional Animal Care and 
Use Committee of Gifu Pharmaceutical University, and the experiments were monitored 
as they were being carried out. 
 
2.6.2 In vivo protocol 
Ophthalmic lipid emulsion (3 μl) was instilled directly onto the left eye of 
unanesthetized mice. The contralateral eye was used as a control and received no 
treatment. After 30 min of instillation, the mice were sacrificed by cervical dislocation, 
and the eyes were enucleated immediately with excess saline washing. The eye balls 
were fixed overnight in 4% paraformaldehyde (Wako, Osaka, Japan) at 4°C and 
immersed into 20% sucrose at 4°C for 48 h. The eye balls were frozen using liquid 
nitrogen and rapidly embedded in optimal cutting temperature (OCT) compound 
(Sakura Finetechnical Co., Ltd., Tokyo, Japan). The frozen eye balls were kept in a 
−20°C refrigerator prior to slicing and observation. A cryostat (CM1850, Leica 
Instrument GmbH, Nussloch, Germany) was used to slice the embedded eye balls into 
10 μm sections. The sliced frozen sections were placed on glass slides, FluoromountTM 
(DBS, Pleasanton, CA, USA) was added, and they were covered with a glass cover slip.  
 
2.6.3 Observation and evaluation on the drug posterior segment delivery efficiency 
The retinal image was observed by fluorescence microscopy (model BZ-9000; Keyence, 
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Osaka, Japan) with a 20 × objective lens or a 4× objective lens for the entire eye 
observation. Coumarin-6 was visualized using a BZ filter GFP (excitation wavelength 
480/30 nm; emission wavelength 510 nm). The fluorescence intensity of coumarin-6 in 
the inner plexiform layer (IPL), at a distance between 475 and 525 μm (50 μm × 50 μm) 
from the optic disc, was evaluated by appropriately calibrated computerized image 
analysis using median density as an analytic tool (Image Processing and Analysis in 
Java; Image J, National Institute of Mental Health, Bethesda, MD, USA). The IPL is a 
suitable target for evaluating retinal delivery because it is located very close to the 
ganglion cell layer (GCL). GCL contains retinal ganglion cells (RGCs) and amacrine 
cells. The death of RGCs is a common feature of many ophthalmic disorders, such as 
glaucoma, optic neuropathy, and retinal vein occlusion. The fluorescence intensity of 
coumarin-6 in the range of 0–255 was considered as the mean density in a constant area 
(50 μm × 50 μm) using Image J. The fluorescence intensity of treated samples was 
calculated relative to that of the untreated sample, which was adjusted to 1. 
 
2.7 In vitro release study 
The release profiles of C-6 from the lipid emulsion were performed in phosphate buffer 
solution (pH 7.4) using the dialysis method. The fresh prepared lipid emulsion was 
poured into cellulose ester dialysis bag (MWCO: 2000Da, Spectrum, USA) against 50 
mL of simulated tears [53] with gentle stirring at 37°C. At pre-determined time intervals, 
aliquots (0.5 ml) were withdrawn and replaced with fresh release medium. The amount 
of C-6 released was determined using fluorescence spectrometry. 
 
2.8 Statistical analysis 
Statistical analyses were carried out using SPSS statistical software (IBM, SPSS 
statistics, Ver. 20.0). Multiple comparisons between different formulation groups and 
their significance were analyzed using ANOVA followed by independent sample t test. 
Data are shown as the mean ± SEM. A difference was considered to be statistically 
significant when the P value was less than 0.05. 
 
Chapter 3 
3.1 Materials 
Vitamin E TPGS and DSPE-PEG2000 were obtained from BASF (Ludwigshafen, 
Germany) and NOF Corporation (Tokyo, Japan), respectively. Coumarin-6, as a model 
drug, was purchased from MP Biomedicals LLC (Illkirch, France). Hank’s balanced salt 
solution (HBSS) was purchased from GIBCO BRL (Grand Island, NY, USA). All other 
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chemicals were commercial products of the reagent grade. 
 
3.2 Preparation of TPGS/DSPE-PEG polymeric micelles 
Two kinds of micelle-forming block copolymer, TPGS and DSPE-PEG, were used to 
prepare by the film casting method as described previously, with minor modifications. 
Briefly, both of micellar-forming materials (TPGS and DSPE-PEG with molar ratios of 
9:0, 6:3, 3:6, and 0:9) in desired concentration (final 6.6 mM) with 0.05 mg/ml 
coumarin-6 were dissolved in 5 ml of methanol and 5 ml of chloroform in a 
round-bottom flask. The organic solvent was removed by evaporation under vacuum to 
obtain a thin film, and the film was then dried in a vacuum oven overnight to ensure 
complete removal of the organic solvent. The resulted film was hydrated with PBS pH 
7.4 in a water bath at 40°C for 10 min. Un-entrapped coumarin-6 was removed by 
centrifugation at 5000 rpm for 10 min at 4°C. The blank micelles were prepared in the 
same way except that coumarin-6 was eliminated. 
 
3.3 Determination of particle size and zeta potential 
The diameter of TPGS/DSPE-PEG polymeric micelles and the zeta potential were 
analyzed using Zetasizer Nano-ZS (Malvern Instrument Ltd., Worcestershire, UK) 
without dilution at room temperature. 
 
3.4 Morphology study  
The morphology of micelles was observed via transmission electron microscopy (JEOL 
JEM-1400Plus, JEOL Ltd, Tokyo, Japan) following negative staining with 2% sodium 
phosphotungstate solution (pH 7.0). 
 
3.5 Cytotoxicity study 
The in vitro cytotoxicity of blank and C-6-loaded micelles against the human 
conjunctiva cells (Wong-Kilbourne derivative of Chang conjunctiva, clones 1 to 5c-41, 
CCL-20.2; American Type Culture Collection, Manassas, VA, USA) were tested by the 
MTS assay. The conjunctiva cells were seeded at a density of 9.6 × 10
3
 cells/well in 
96-well transparent plates and incubated for 24 h under standard cell culture conditions. 
After the attachment period, medium was removed by washing twice with HBSS 
solution. The medium was then changed to TPGS/DSPE-PEG micelles. After 2 h of 
incubation, the cells were rinsed with HBSS three times to wash out the sample. Then, 
the cells were incubated with 120 μl of MTS solution (317μg/ml in medium) at 37°C in 
a CO2 incubator for another 2 h. Absorbance values were measured with a microplate 
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reader (MTP 120, Corona Electric, Tokyo, Japan) at a wavelength of 490 nm. 
 
3.6 In vitro release study 
The measurements of the degree of drug release are based on the increase of C-6 
fluorescence intensity in mediums when C-6 is transferred from the dialysis bag to the 
outer mediums. Briefly, the sample (1 ml) was poured into cellulose ester dialysis 
membrane bags, with a cutoff molecular weight of 2000 Da, (Spectrum, USA) and it 
was dialyzed against 100 ml of water containing Tween 80 (1% w/v), with gentle 
stirring at 37°C. At pre-determined time intervals, aliquots (0.5 ml) were withdrawn and 
replaced with fresh release medium. The amount of C-6 released was determined using 
fluorescence spectrometry. 
 
3.7 Cell uptake study 
Cells were seeded 24 h prior to treatment in 8-well chamber slides, with an initial 
density of 1.05 × 10
5
 cells/well. After 30 min, 1 h, and 2 h of exposure to 200 μl of 6.6 
mM freshly prepared micelle solutions at 37°C in a CO2 incubator, cells were rinsed 
twice with PBS. Then, fixed using 4% PFA and incubated for 30 min at room 
temperature. Cells were observed to identify the cellular association of micelles and 
their intracellular locations using CLSM. 
 
3.8 Endocytosis inhibition study 
As the method of 3.7, before exposure to the polymeric micelles, conjunctiva cells were 
pretreated with 10μg/mL chlorpromazine for 1 h to inhibit clathrin and 1μg/mL filipin 
III for 1 h to inhibit caveolae endocytosis. Then treat with 200 μL 3:6 micelles for 1 h. 
After these processes, the endocytosis inhibition study was carried out with the same 
method as 3.7.  
 
3.9 Animal study 
In this study animal study carried out with the same condition as 2.5.  
 
3.10 Statistical analysis 
Statistical analyses were performed using SPSS statistical software (IBM, SPSS 
statistics, Ver. 20.0). Multiple comparisons between different groups and their 
significance were analyzed using ANOVA followed by independent sample t-tests. Data 
are presented as the mean ± SEM. A difference was considered statistically significant 
when the P value was less than 0.05. 
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